Wordt geladen...
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
Gemtuzumab ozogamicin (Mylotarg; Pfizer, New York, NY) was the first antibody–drug conjugate to be approved for CD33‐positive acute myeloid leukemia (AML). However, it was voluntarily withdrawn from the US market due to lack of clinical benefit in the confirmatory phase III trial. In 2012, several i...
Bewaard in:
| Gepubliceerd in: | Clin Pharmacol Ther |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852000/ https://ncbi.nlm.nih.gov/pubmed/31070776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1500 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|